2023-07-21T10:38:45-04:00 2022-12-31 461041593 FINANCIAL SOLUTION ADVISORS PLLC 4350 PABLO PROFESSIONAL CT STE 200 JACKSONVILLE FL 322243224 990 2022-01-01 341710663 CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION CLEV 2167913800 10701 EAST BOULEVARD CLEVELAND OH 44106 YNGVE FALCK-YTTER MD TREASURER 2167912300 2023-05-30 true YNGVE FALCK YTTER 999009999 true MICHAEL B MCLEOD CPA P00966646 9042962024 2023-07-21 2022 2023-04-26 12:10:37Z JILL K D MELLON JD MBA FACH 10701 EAST BLVD CLEVELAND OH 44106 3836219 false X N/A X 1991 OH THE PRIMARY TAX-EXEMPT PURPOSE OF THE CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION, A 501(C)(3) MEDICAL RESEARCH FOUNDATION ESTABLISHED IN ACCORDANCE WITH TITLE 38, SUBCHAPTER IV-RESEARCH AND EDUCATION CORPORATIONS, SECTIONS 7361-7368, IS TO SUPPORT BIOMEDICAL RESEARCH AT THE LOUIS STOKES CLEVELAND VA MEDICAL CENTER. 7 2 61 0 23164 78 4124537 3823426 6036 12715 0 4153737 3836219 0 0 2544232 2692038 0 0 1945277 2313462 4489509 5005500 -335772 -1169281 5763350 4723141 917603 1047072 4845747 3676069 X THE PRIMARY TAX-EXEMPT PURPOSE OF THE CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION, A 501(C)(3) MEDICAL RESEARCH FOUNDATION ESTABLISHED IN ACCORDANCE WITH TITLE 38, SUBCHAPTER IV-RESEARCH AND EDUCATION CORPORATIONS, SECTIONS 7361-7368, IS TO SUPPORT BIOMEDICAL AND CLINICAL RESEARCH AS WELL AS TO PROVIDE HEALTH-RELATED EDUCATIONAL ACTIVITIES IN CONJUNCTION WITH THE LOUIS STOKES CLEVELAND DEPARTMENT OF VA MEDICAL CENTER (VAMC). RESEARCH SPONSORED BY THE CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION BENEFITS VETERANS TREATED AT THE LOUIS STOCKS CLEVELAND VAMC AND THE GENERAL PUBLIC BY ADVANCING KNOWLEDGE IN THE DIAGNOSIS AND TREATMENT OF DISEASE AND DISABILITY. EDUCATION PROGRAMS SUPPORTED BY THE CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION HELP DISSEMINATE THE RESULTS OF RESEARCH SO THEY MAY BE TRANSLATED TO CLINICAL PRACTICE, PROVIDE HOSPITAL STAFF WITH TRAINING IN THE LATEST TREATMENTS, AND HELP PATIENTS UNDERSTAND AND MANAGE THEIR MEDICAL CONDITIONS. false false 214953 DR. ELIZABETH FINE SMILOVICH, GERIATRICIAN AT THE CLEVELAND VA RECEIVED A SUBAWARD FROM THE ARNOLD FOUNDATION THROUGH UNIVERSITY OF PENNSYLVANIA TO STUDY THE REPLICATION OF THE TRANSITIONAL CARE MODEL (TCM) VIA A RANDOMIZED CONTROL TRIAL CONDUCTED ACROSS FOUR HEALTH SYSTEMS WITH A TOTAL OF 1,600 ENROLLED PATIENTS. THIS STUDY WAS ALSO SUPPORTED IN PART BY THE VA HEALTH SERVICES RESEARCH AND DEVELOPMENT SERVICE. THE PURPOSE OF THE TRANSITIONAL CARE MODEL IS TO EXPLORE THE ADVANCED PRACTICE REGISTERED NURSES (APRNS) ROLE WITH PATIENTS AND THEIR FAMILY CAREGIVERS AFTER DISCHARGE FROM THE HOSPITAL, AND TO SEE IF THEIR INVOLVEMENT IN POST-DISCHARGE MEDICAL MANAGEMENT MAY IMPROVE THE PATIENTS' EXPERIENCE AND ENHANCE THEIR HEALTH OUTCOMES. THE STUDY ENROLLED PARTICIPANTS 65 YEARS AND OLDER AND WHO HAD BEEN ADMITTED TO THE HOSPITAL WITH PNEUMONIA OR A HISTORY OF HEART FAILURE AND COPD OR WHOSE SYMPTOMS SUGGESTED A NEW HEART FAILURE OR COPD DIAGNOSIS. ONCE A PARTICIPANT SIGNED THE CONSENT FORM, THEY WERE RANDOMLY ASSIGNED INTO THE CONTROL GROUP OR INTERVENTION GROUP. THE CONTROL GROUP WAS GIVEN A QUESTIONNAIRE WHILE IN THE HOSPITAL AND 90-DAYS POST HOSPITAL DISCHARGE. PARTICIPANTS IN THE INTERVENTION GROUP WERE GIVEN THE SAME QUESTIONNAIRE BUT ALSO ASSIGNED AN APRN TO COORDINATE THEIR CARE FOR 60-90 DAYS AFTER DISCHARGE. THE APRN WORKED WITH THE PARTICIPANTS VA HEALTH CARE TEAM TO ASSESS THEIR MEDICAL NEEDS, COORDINATE SERVICES, AND ASSIST IN DESIGNING AND IMPLEMENTING THE PLAN OF CARE. THE APRN ALSO ATTENDED THE PARTICIPANTS FIRST AND SOMETIMES SUBSEQUENT FOLLOW-UP APPOINTMENTS POST-DISCHARGE. DR. FINE SMILOVICH AND HER TEAM ENROLLED 194 SUBJECTS INTO THIS STUDY OVER A TWO-YEAR PERIOD. INITIAL ANALYSIS IS SHOWING PROMISING RESULTS FROM THE APRN INVOLVEMENT. PRELIMINARY DATA SHOWS THAT ONLY ABOUT 16% OF PARTICIPANTS IN THE INTERVENTION GROUP HAD REHOSPITALIZATIONS 30-DAYS POST DISCHARGE COMPARED TO THE CONTROL GROUP AT ABOUT 22% REHOSPITALIZATION RATE. 172291 DR. KATARINA GREER, GASTROENTEROLOGIST AT THE CLEVELAND VA, RECEIVED A DOD PEER REVIEWED CANCER RESEARCH PROGRAM (PRCRP) IMPACT AWARD IN 2021. THE GRANT ENTITLED "NONENDOSCOPIC SCREENING TO IMPACT ESOPHAGEAL CANCER IN VETERANS" IS A THREE-YEAR GRANT THAT STARTED IN EARLY 2022. THIS IS THE FOUNDATION'S FIRST CLINICAL DOD AWARD. BACKGROUND: ESOPHAGEAL ADENOCARCINOMA (EAC) HAS INCREASED MORE THAN 6-FOLD IN THE PAST FOUR DECADES. THE INCORPORATION OF A NON-ENDOSCOPIC DETECTION METHOD IN PRIMARY CARE PRACTICE WILL INCREASE THE POSITIVE PREDICTIVE VALUE OF EGD AND INCREASE THE DETECTION OF BARRETT'S ESOPHAGUS (BE). THIS STUDY WILL AIM TO DETERMINE SENSITIVITY, SPECIFICITY, AND POSITIVE PREDICTIVE VALUE OF ESOCHECK SAMPLING DEVICE ESOGUARD (DNA MARKER PANEL LABORATORY DIAGNOSTIC TEST) PERFORMED IN ROUTINE PRACTICE FOR DETECTING BE IN AN AT- RISK POPULATION. THE SECOND AIM OF THE STUDY IS TO COMPARE THE YIELD OF DETECTED BE USING AN ESOCHECK/ESOGUARD STRATEGY VERSUS STANDARD EGD ALONE STRATEGY IN ROUTINE PRACTICE IN AT-RISK POPULATIONS AT THE CLEVELAND VA SHORT TERM IMPACT: THE EXPECTED OUTCOME OF THE PROPOSED WORK IS THE GATHERING OF DETAILED INFORMATION ABOUT THE TEST PERFORMANCE CHARACTERISTICS, I.E. SENSITIVITY, SPECIFICITY, POSITIVE AND NEGATIVE PREDICTIVE VALUE. SHOULD THE SCREENING TEST PERFORM WELL, ESOCHECK/ESOGUARD TEST WOULD BE PRODUCED ON A LARGER SCALE, ITS MOLECULAR DIAGNOSTICS PROCESS WOULD BE AUTOMATED, DRIVING COSTS OF THE SCREENING DEVICE DOWN. TEST INDICATION COULD BE EXPANDED TO ALL OBESE PATIENTS OLDER THAN 50 WITHOUT A HISTORY OF CHRONIC GERD, EXPLORING THE PREVALENCE OF BE/ECA IN ASYMPTOMATIC INDIVIDUALS. LONG TERM IMPACT: FOLLOWING SUCCESSFUL VALIDATION OF THE PROPOSED NON- INVASIVE SCREENING METHOD, THE TEST COULD BE USED AS TRIAGING TOOL FOR ENDOSCOPY IN ESOPHAGEAL CANCER SCREENING. IMPLEMENTATION OF AN OFFICE BASED UNSEDATED TEST WOULD ALSO ENABLE SCREENING OF A BROADER POPULATION. PATIENTS WITH POSITIVE MOLECULAR TESTING, SUGGESTIVE OF THE PRESENCE OF METHYLATED DNA WOULD UNDERGO DIAGNOSTIC UPPER ENDOSCOPY. THIS TEST WOULD LIKELY IDENTIFY BE, BE WITH DYSPLASIA, OR EARLY ESOPHAGEAL CANCER. PATIENTS WITH DYSPLASTIC TISSUE WOULD BE ELIGIBLE FOR ENDOSCOPIC TREATMENT METHODS, INCLUDING ENDOSCOPIC MUCOSAL RESECTION OR RADIOFREQUENCY ABLATION. PATIENTS WITH DEEPER TISSUE INVOLVEMENT COULD STILL PROCEED TO SURGERY, RECEIVE CHEMOTHERAPY OR RADIATION. TREATMENT OPTIONS OTHER THAN PALLIATIVE CARE WOULD BE AVAILABLE LEADING TO IMPROVED DISEASE-FREE SURVIVAL. 24782 DR. VEIZI, CHIEF OF PAIN MEDICINE, AT THE CLEVELAND VA, RECEIVED AN NIH SUBAWARD THROUGH JOHNS HOPKINS UNIVERSITY FOR A MULTICENTER STUDY TITLED "A SEQUENCED-STRATEGY FOR IMPROVING OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS PAIN" SKOAP STUDY. SKOAP IS A NATIONAL STUDY FUNDED BY THE HELPING ADDICTION LONG-TERM INITIATIVE OR NIH HEAL INITIATIVE. BACKGROUND: THE PURPOSE OF THE SKOAP STUDY (CLINICALTRIALS.GOV-NCT04504812) IS TO COMPARE DIFFERENT TREATMENT OPTIONS FOR PEOPLE LIVING WITH KNEE OSTEOARTHRITIS PAIN. THE GOAL IS TO REDUCE PAIN AND IMPROVE FUNCTION USING CONSERVATIVE TREATMENT AND IF NEEDED, NON-SURGICAL PROCEDURAL TREATMENTS. PROCESS: THIS STUDY HAS TWO PHASES 2700 PATIENTS AND BOTH PHASES COMPARE DIFFERENT NON-SURGICAL TREATMENTS FOR KNEE OSTEOARTHRITIS PAIN. PHASE 1: PEOPLE WHO PARTICIPATE ARE RANDOMIZED TO ONE OF THREE GROUPS: 1. BEST PRACTICES 2. DULOXETINE (AN ORAL MEDICATION USED TO IMPROVE PAIN) OR 3. ONLINE COPING SKILLS TRAINING. PHASE 2: PEOPLE WHO PARTICIPATE ARE RANDOMIZED INTO ONE OF THREE GROUPS. 1. JOINT INJECTION 2. NERVE BLOCK OR 3. NERVE ABLATION. THE IMPORTANCE OF SKOAP: THERE IS AN URGENT PUBLIC HEALTH NEED TO FIND CLINICALLY PROVEN TREATMENTS TO IMPROVE QUALITY OF LIFE AND REDUCE RELIANCE ON OPIOIDS, FOR LONG-TERM PAIN MANAGEMENT FOR PATIENTS SUFFERING FROM KNEE OA. THIS EFFECTIVENESS TRIAL WILL COMPARE AVAILABLE TREATMENTS FOR PAIN REDUCTION AND FUNCTIONAL IMPROVEMENT IN PATIENTS WITH KNEE OSTEOARTHRITIS. THE RESULTS CAN LEAD TO IMPROVED PATIENT SELECTION AND INFORM EVIDENCE- BASED GUIDANCE BY OFFERING WELL-TESTED, EFFECTIVE, NON-OPIOID ALTERNATIVES. DR. VEIZI IS A MEMBER OF THE NATIONAL EXECUTIVE COMMITTEE FOR THE SKOAP STUDY. SINCE JOINING THE STUDY, DR. VEIZI AND HIS TEAM, INCLUDING MS. STOUT, CNP AND MS. MECKLEY, RN AS RESEARCH COORDINATORS, DAMIEN KETER, PT AND DR. GANDHI AS SITE CO-I, HAVE BEEN RECOGNIZED MULTIPLE TIMES FOR THEIR IMPRESSIVE WORK IN EXCEEDING ENROLLMENT GOALS. 3712518 OTHER RESEARCH AND SERVICE ACTIVITIES. 3712518 4124544 true false false false false false false false false false false false false false false true true false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false true 6 0 61 true false false false false false false false false false false false false false false X 7 2 false false false false false false false true true false false true true true true true false true false false OH X JEFF MOORE PHD 2167913800 10701 EAST BLVD CLEVELAND OH 44106 BRIGID WILSON PHD HCE 40.00 X 120978 0 30103 JEFF MOORE PHD EXECUTIVE DI 40.00 X 126983 0 13210 RICHARD DECHANT TRUSTEE/DIRE 1.00 X 0 0 0 JILL K D MELLON JD MBA FACH PRESIDENT 1.00 X X 0 0 0 GEORGE JASKIW MD SECRETARY 1.00 X X 0 0 0 MURRAY ALTOSE MD TRUSTEE/DIRE 1.00 X 0 0 0 SIMRAN SINGH MD TRUSTEE/DIRE 1.00 X 0 0 0 YNGVE FALCK-YTTER MD TREASURER 1.00 X X 0 0 0 NEAL PEACHEY PHD VICE PRESIDE 1.00 X X 0 0 0 247961 43313 2 false true false 78 78 FEDERAL CONT & GRANT REV 541700 1956758 1956758 NON-FEDERAL CONT & GRANT REV 541700 1570463 1570463 IPA REVENUE 541700 296205 296205 3823426 12715 12715 3836219 3836141 X 126983 126983 2013370 1559288 454082 53277 32894 20383 323743 218832 104911 174665 127011 47654 19205 19205 1755937 1706835 49102 25352 15352 10000 27333 17569 9764 48436 31373 17063 58560 45188 13372 5058 5058 RESEARCH STUDY COSTS 275116 271737 3379 STUDY ADJUSTMENTS 78175 78175 EQUIPMENT & REPAIRS 20290 20290 5005500 4124544 880956 0 3299557 1207159 200296 997899 2240642 2501011 22855 17072 5763350 4723141 777673 844079 139930 202993 917603 1047072 X 4845747 3676069 4845747 3676069 5763350 4723141 -1169281 -397 X false true X false true true X CLEVELAND VA MEDICAL CENTER CLEVELAND OH X 3835822 -397 -397 3836219 3836219 5005500 5005500 5005500 SCHEDULE D, PAGE 3, PART X THE FOUNDATION QUALIFIES AS A TAX-EXEMPT ORGANIZATION UNDER SECTION 501(C) (3) OF THE INTERNAL REVENUE CODE (IRC). THE FOUNDATION PERIODICALLY ASSESSES WHETHER IT HAS INCURRED INCOME TAX EXPENSE OR RELATED INTEREST OR PENALTIES IN ACCORDANCE WITH ACCOUNTING FOR UNCERTAIN TAX POSITIONS. NO SUCH AMOUNTS WERE RECOGNIZED FOR THE YEARS ENDING DECEMBER 31, 2022 AND 2021, RESPECTIVELY. SHOULD THE FOUNDATIONS TAX-EXEMPT STATUS BE CHALLENGED IN THE FUTURE, THE FOUNDATIONS 2020, 2021, AND 2022 TAX YEARS ARE OPEN FOR EXAMINATION BY THE IRS. false false false false false false false false false BRIGID WILSON PHD HCE 120978 30103 151081 FORM 990 - ORGANIZATION'S MISSION THE PRIMARY TAX-EXEMPT PURPOSE OF THE CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION, A 501(C)(3) MEDICAL RESEARCH FOUNDATION ESTABLISHED IN ACCORDANCE WITH TITLE 38, SUBCHAPTER IV-RESEARCH AND EDUCATION CORPORATIONS, SECTIONS 7361-7368, IS TO SUPPORT BIOMEDICAL AND CLINICAL RESEARCH AS WELL AS TO PROVIDE HEALTH-RELATED EDUCATIONAL ACTIVITIES IN CONJUNCTION WITH THE LOUIS STOKES CLEVELAND DEPARTMENT OF VA MEDICAL CENTER (VAMC). RESEARCH SPONSORED BY THE CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION BENEFITS VETERANS TREATED AT THE LOUIS STOCKS CLEVELAND VAMC AND THE GENERAL PUBLIC BY ADVANCING KNOWLEDGE IN THE DIAGNOSIS AND TREATMENT OF DISEASE AND DISABILITY. EDUCATION PROGRAMS SUPPORTED BY THE CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION HELP DISSEMINATE THE RESULTS OF RESEARCH SO THEY MAY BE TRANSLATED TO CLINICAL PRACTICE, PROVIDE HOSPITAL STAFF WITH TRAINING IN THE LATEST TREATMENTS, AND HELP PATIENTS UNDERSTAND AND MANAGE THEIR MEDICAL CONDITIONS. FORM 990, PAGE 2, PART III, LINE 4A DR. ELIZABETH FINE SMILOVICH, GERIATRICIAN AT THE CLEVELAND VA RECEIVED A SUBAWARD FROM THE ARNOLD FOUNDATION THROUGH UNIVERSITY OF PENNSYLVANIA TO STUDY THE REPLICATION OF THE TRANSITIONAL CARE MODEL (TCM) VIA A RANDOMIZED CONTROL TRIAL CONDUCTED ACROSS FOUR HEALTH SYSTEMS WITH A TOTAL OF 1,600 ENROLLED PATIENTS. THIS STUDY WAS ALSO SUPPORTED IN PART BY THE VA HEALTH SERVICES RESEARCH AND DEVELOPMENT SERVICE. THE PURPOSE OF THE TRANSITIONAL CARE MODEL IS TO EXPLORE THE ADVANCED PRACTICE REGISTERED NURSES (APRNS) ROLE WITH PATIENTS AND THEIR FAMILY CAREGIVERS AFTER DISCHARGE FROM THE HOSPITAL, AND TO SEE IF THEIR INVOLVEMENT IN POST-DISCHARGE MEDICAL MANAGEMENT MAY IMPROVE THE PATIENTS' EXPERIENCE AND ENHANCE THEIR HEALTH OUTCOMES. THE STUDY ENROLLED PARTICIPANTS 65 YEARS AND OLDER AND WHO HAD BEEN ADMITTED TO THE HOSPITAL WITH PNEUMONIA OR A HISTORY OF HEART FAILURE AND COPD OR WHOSE SYMPTOMS SUGGESTED A NEW HEART FAILURE OR COPD DIAGNOSIS. ONCE A PARTICIPANT SIGNED THE CONSENT FORM, THEY WERE RANDOMLY ASSIGNED INTO THE CONTROL GROUP OR INTERVENTION GROUP. THE CONTROL GROUP WAS GIVEN A QUESTIONNAIRE WHILE IN THE HOSPITAL AND 90-DAYS POST HOSPITAL DISCHARGE. PARTICIPANTS IN THE INTERVENTION GROUP WERE GIVEN THE SAME QUESTIONNAIRE BUT ALSO ASSIGNED AN APRN TO COORDINATE THEIR CARE FOR 60-90 DAYS AFTER DISCHARGE. THE APRN WORKED WITH THE PARTICIPANTS VA HEALTH CARE TEAM TO ASSESS THEIR MEDICAL NEEDS, COORDINATE SERVICES, AND ASSIST IN DESIGNING AND IMPLEMENTING THE PLAN OF CARE. THE APRN ALSO ATTENDED THE PARTICIPANTS FIRST AND SOMETIMES SUBSEQUENT FOLLOW-UP APPOINTMENTS POST-DISCHARGE. DR. FINE SMILOVICH AND HER TEAM ENROLLED 194 SUBJECTS INTO THIS STUDY OVER A TWO-YEAR PERIOD. INITIAL ANALYSIS IS SHOWING PROMISING RESULTS FROM THE APRN INVOLVEMENT. PRELIMINARY DATA SHOWS THAT ONLY ABOUT 16% OF PARTICIPANTS IN THE INTERVENTION GROUP HAD REHOSPITALIZATIONS 30-DAYS POST DISCHARGE COMPARED TO THE CONTROL GROUP AT ABOUT 22% REHOSPITALIZATION RATE. FORM 990, PAGE 2, PART III, LINE 4B DR. KATARINA GREER, GASTROENTEROLOGIST AT THE CLEVELAND VA, RECEIVED A DOD PEER REVIEWED CANCER RESEARCH PROGRAM (PRCRP) IMPACT AWARD IN 2021. THE GRANT ENTITLED "NONENDOSCOPIC SCREENING TO IMPACT ESOPHAGEAL CANCER IN VETERANS" IS A THREE-YEAR GRANT THAT STARTED IN EARLY 2022. THIS IS THE FOUNDATION'S FIRST CLINICAL DOD AWARD. BACKGROUND: ESOPHAGEAL ADENOCARCINOMA (EAC) HAS INCREASED MORE THAN 6-FOLD IN THE PAST FOUR DECADES. THE INCORPORATION OF A NON-ENDOSCOPIC DETECTION METHOD IN PRIMARY CARE PRACTICE WILL INCREASE THE POSITIVE PREDICTIVE VALUE OF EGD AND INCREASE THE DETECTION OF BARRETT'S ESOPHAGUS (BE). THIS STUDY WILL AIM TO DETERMINE SENSITIVITY, SPECIFICITY, AND POSITIVE PREDICTIVE VALUE OF ESOCHECK SAMPLING DEVICE ESOGUARD (DNA MARKER PANEL LABORATORY DIAGNOSTIC TEST) PERFORMED IN ROUTINE PRACTICE FOR DETECTING BE IN AN AT- RISK POPULATION. THE SECOND AIM OF THE STUDY IS TO COMPARE THE YIELD OF DETECTED BE USING AN ESOCHECK/ESOGUARD STRATEGY VERSUS STANDARD EGD ALONE STRATEGY IN ROUTINE PRACTICE IN AT-RISK POPULATIONS AT THE CLEVELAND VA SHORT TERM IMPACT: THE EXPECTED OUTCOME OF THE PROPOSED WORK IS THE GATHERING OF DETAILED INFORMATION ABOUT THE TEST PERFORMANCE CHARACTERISTICS, I.E. SENSITIVITY, SPECIFICITY, POSITIVE AND NEGATIVE PREDICTIVE VALUE. SHOULD THE SCREENING TEST PERFORM WELL, ESOCHECK/ESOGUARD TEST WOULD BE PRODUCED ON A LARGER SCALE, ITS MOLECULAR DIAGNOSTICS PROCESS WOULD BE AUTOMATED, DRIVING COSTS OF THE SCREENING DEVICE DOWN. TEST INDICATION COULD BE EXPANDED TO ALL OBESE PATIENTS OLDER THAN 50 WITHOUT A HISTORY OF CHRONIC GERD, EXPLORING THE PREVALENCE OF BE/ECA IN ASYMPTOMATIC INDIVIDUALS. LONG TERM IMPACT: FOLLOWING SUCCESSFUL VALIDATION OF THE PROPOSED NON- INVASIVE SCREENING METHOD, THE TEST COULD BE USED AS TRIAGING TOOL FOR ENDOSCOPY IN ESOPHAGEAL CANCER SCREENING. IMPLEMENTATION OF AN OFFICE BASED UNSEDATED TEST WOULD ALSO ENABLE SCREENING OF A BROADER POPULATION. PATIENTS WITH POSITIVE MOLECULAR TESTING, SUGGESTIVE OF THE PRESENCE OF METHYLATED DNA WOULD UNDERGO DIAGNOSTIC UPPER ENDOSCOPY. THIS TEST WOULD LIKELY IDENTIFY BE, BE WITH DYSPLASIA, OR EARLY ESOPHAGEAL CANCER. PATIENTS WITH DYSPLASTIC TISSUE WOULD BE ELIGIBLE FOR ENDOSCOPIC TREATMENT METHODS, INCLUDING ENDOSCOPIC MUCOSAL RESECTION OR RADIOFREQUENCY ABLATION. PATIENTS WITH DEEPER TISSUE INVOLVEMENT COULD STILL PROCEED TO SURGERY, RECEIVE CHEMOTHERAPY OR RADIATION. TREATMENT OPTIONS OTHER THAN PALLIATIVE CARE WOULD BE AVAILABLE LEADING TO IMPROVED DISEASE-FREE SURVIVAL. FORM 990, PAGE 2, PART III, LINE 4C DR. VEIZI, CHIEF OF PAIN MEDICINE, AT THE CLEVELAND VA, RECEIVED AN NIH SUBAWARD THROUGH JOHNS HOPKINS UNIVERSITY FOR A MULTICENTER STUDY TITLED "A SEQUENCED-STRATEGY FOR IMPROVING OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS PAIN" SKOAP STUDY. SKOAP IS A NATIONAL STUDY FUNDED BY THE HELPING ADDICTION LONG-TERM INITIATIVE OR NIH HEAL INITIATIVE. BACKGROUND: THE PURPOSE OF THE SKOAP STUDY (CLINICALTRIALS.GOV-NCT04504812) IS TO COMPARE DIFFERENT TREATMENT OPTIONS FOR PEOPLE LIVING WITH KNEE OSTEOARTHRITIS PAIN. THE GOAL IS TO REDUCE PAIN AND IMPROVE FUNCTION USING CONSERVATIVE TREATMENT AND IF NEEDED, NON-SURGICAL PROCEDURAL TREATMENTS. PROCESS: THIS STUDY HAS TWO PHASES 2700 PATIENTS AND BOTH PHASES COMPARE DIFFERENT NON-SURGICAL TREATMENTS FOR KNEE OSTEOARTHRITIS PAIN. PHASE 1: PEOPLE WHO PARTICIPATE ARE RANDOMIZED TO ONE OF THREE GROUPS: 1. BEST PRACTICES 2. DULOXETINE (AN ORAL MEDICATION USED TO IMPROVE PAIN) OR 3. ONLINE COPING SKILLS TRAINING. PHASE 2: PEOPLE WHO PARTICIPATE ARE RANDOMIZED INTO ONE OF THREE GROUPS. 1. JOINT INJECTION 2. NERVE BLOCK OR 3. NERVE ABLATION. THE IMPORTANCE OF SKOAP: THERE IS AN URGENT PUBLIC HEALTH NEED TO FIND CLINICALLY PROVEN TREATMENTS TO IMPROVE QUALITY OF LIFE AND REDUCE RELIANCE ON OPIOIDS, FOR LONG-TERM PAIN MANAGEMENT FOR PATIENTS SUFFERING FROM KNEE OA. THIS EFFECTIVENESS TRIAL WILL COMPARE AVAILABLE TREATMENTS FOR PAIN REDUCTION AND FUNCTIONAL IMPROVEMENT IN PATIENTS WITH KNEE OSTEOARTHRITIS. THE RESULTS CAN LEAD TO IMPROVED PATIENT SELECTION AND INFORM EVIDENCE- BASED GUIDANCE BY OFFERING WELL-TESTED, EFFECTIVE, NON-OPIOID ALTERNATIVES. DR. VEIZI IS A MEMBER OF THE NATIONAL EXECUTIVE COMMITTEE FOR THE SKOAP STUDY. SINCE JOINING THE STUDY, DR. VEIZI AND HIS TEAM, INCLUDING MS. STOUT, CNP AND MS. MECKLEY, RN AS RESEARCH COORDINATORS, DAMIEN KETER, PT AND DR. GANDHI AS SITE CO-I, HAVE BEEN RECOGNIZED MULTIPLE TIMES FOR THEIR IMPRESSIVE WORK IN EXCEEDING ENROLLMENT GOALS. FORM 990, PAGE 2, PART III, LINE 4D OTHER RESEARCH AND SERVICE ACTIVITIES. FORM 990, PAGE 6, PART VI, LINE 11B FORM 990 IS DISTRIBUTED TO THE BOARD OF DIRECTORS AND IS REVIEWED, DISCUSSED, AND APPROVED. FORM 990, PAGE 6, PART VI, LINE 12C THE ORGANIZATION IS REQUIRED BY THE U.S. DEPARTMENT OF VETERANS AFFAIRS TO MONITOR ITS CONFLICT OF INTEREST POLICY THROUGH ANNUAL CONFLICT OF INTEREST AND ETHICS CERTIFICATIONS. FORM 990, PAGE 6, PART VI, LINE 15A THE ORGANIZATION HAS ONLY ONE COMPENSATED OFFICER, THE EXECUTIVE DIRECTOR. AN ANNUAL REVIEW OF COMPENSATION FOR SIMILAR NPO RESULTS IN THE APPLICATION OF A COST OF LIVING INCREASE IN THE CLEVELAND AREA. THE AMOUNT OF THE EXECUTIVE DIRECTOR'S SALARY THUS CALCULATED IS INCLUDED IN THE BUDGET WHICH IS APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE FOR INSPECTION UPON WRITTEN REQUEST. THE ORGANIZATION DOES NOT GENERALLY MAKE ITS ORGANIZING DOCUMENTS OR CONFLICT OF INTEREST POLICY AVAILABLE TO THE GENERAL PUBLIC. FORM 990, PART IX, LINE 11G CONSULTING FEES 2,370 45,508 0 OUTSIDE STUDY FEES 1,666,812 0 0 PAYROLL PROCESSING FEES 5,497 3,594 0 SUBJECT PAYMENT 32,156 0 0 TOTAL 1,706,835 49,102 0